Premium
Minimal residual disease monitoring after allogeneic transplantation may help to individualize post‐transplant therapeutic strategies in acute myeloid malignancies
Author(s) -
DíezCampelo María,
PérezSimón José Antonio,
Pérez Jose,
Alcoceba Miguel,
Richtmon Juan,
Vidriales Belén,
San Miguel Jesús
Publication year - 2009
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.21340
Subject(s) - medicine , minimal residual disease , transplantation , myeloid leukemia , oncology , multivariate analysis , disease , myeloid , myelodysplastic syndromes , leukemia , bone marrow
Abstract This study evaluates the prognostic value of minimal residual disease (MRD) monitoring by multiparametric flow cytometry in 41 patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic transplantation. MRD assessment after transplant (day +100) allowed to discriminate different risk populations, being the most significant cut‐off value for outcome level of MRD